What is the future for rimonabant in the treatment of obesity
| Data(s) |
01/12/2008
|
|---|---|
| Resumo |
Orlistat and sibutramine only cause modest reductions in body weight. Rimonabant, a cannabinoid receptor 1 antagonist, is a new approach to weight reduction, but is it safe, efficacious, and better than the existing agents? |
| Formato |
application/pdf |
| Identificador | |
| Publicador |
Bryn Mawr Communications |
| Relação |
http://eprints.qut.edu.au/29619/1/c29619.pdf http://www.reviewofendo.com/articles/1208/ Doggrell, Sheila (2008) What is the future for rimonabant in the treatment of obesity. Review of Endocrinology, December, pp. 14-17. |
| Direitos |
Copyright 2008 Bryn Mawr Communications |
| Fonte |
Faculty of Science and Technology; School of Life Sciences |
| Palavras-Chave | #111502 Clinical Pharmacology and Therapeutics #rimonabant #obesity |
| Tipo |
Journal Article |
